Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar

This article was originally published in The Gray Sheet

Executive Summary

FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis

Related Content

Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Research In Brief
CDRH To Abandon Bad Precedents On Path To Predictable 510(k)s
Neuronetics' NeuroStar Depression Therapy Not Backed By Data - Blues
Reimbursement In Brief
Pico-Tesla To File De Novo 510(k) In 2011 To Treat Parkinson's With Magnets
Financings In Brief
Transcranial Magnetic Stimulation Device Gets Drafted By Army
Psychiatric Devices: Medtronic OCD Approval, Depression Trial Announced
Neuronetics Anti-Depression Device Not Equivalent To Shock Therapy – Panel



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts